Pierre Fabre Laboratories Reports the EC’s Approval of Braftovi Plus Mektovi to Treat Advanced Non-Small Cell Lung Cancer
Shots:
- The EC has approved Braftovi + Mektovi to treat advanced NSCLC adults with BRAFV600E mutation, supported by the P-II (PHAROS) study
- The P-II (PHAROS) study assessed safety & efficacy of Braftovi (450mg, QD) + Mektovi (45mg, BID) in BRAFV600E mutated advanced NSCLC patients, either naïve or treated with Pt-based CT and/or anti-PD-1/PD-L1 inhibitor therapy
- Study reached the 1EP, depicting ORR of 75% (CRs: 15%, PRs: 59%) & mDoR of 40mos. during primary analysis (as of Sep 2022) in treatment-naïve population (n=59), with 64% of them maintaining it for at least 12mos. In treatment-experienced group (n=39), ORR was 46% (CRs: 10%, PRs: 36%) & mDoR of 16.7mos., with 44% maintaining it for at least 12mos.
Ref: Pierre Fabre Laboratories | Image: Pierre Fabre Laboratories
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
